Capivast 200 mg (Capivasertib) | Targeted Therapy for Advanced HR-Positive, HER2-Negative Breast Cancer

Capivast 200 mg (Capivasertib)

Capivast 200 mg is an oral targeted anticancer medicine containing Capivasertib 200 mg, a highly selective AKT inhibitor developed to treat certain patients with HR-positive, HER2-negative advanced or metastatic breast cancer. Manufactured by Everest Pharmaceuticals Ltd., Capivast 200 mg is designed to interrupt abnormal cellular signaling pathways that promote cancer cell growth, survival, and resistance to hormone therapy.

Unlike conventional chemotherapy, Capivast 200 mg works by specifically blocking the AKT protein within the PI3K/AKT signaling pathway. This targeted mechanism helps slow tumor progression while minimizing damage to healthy cells. The medicine is commonly prescribed in combination with Fulvestrant for adults whose breast cancer has progressed after endocrine (hormone) therapy.

For patients whose tumors carry PIK3CA, AKT1, or PTEN genetic alterations, Capivast 200 mg offers an important precision medicine option. By targeting these molecular abnormalities, it may improve treatment response and delay disease progression while enhancing the effectiveness of endocrine therapy.

What is Capivast 200 mg?

Capivast 200 mg contains Capivasertib, an innovative targeted therapy belonging to the class of AKT inhibitors. AKT is a protein kinase that plays a central role in the PI3K/AKT signaling pathway, which regulates numerous essential cellular functions, including:

• Cell growth
• Cell division
• Cell metabolism
• Cell survival
• Tissue repair
• Cellular proliferation

In healthy cells, this pathway helps maintain normal biological processes. However, genetic mutations can cause the pathway to become overactive in many cancers, particularly advanced breast cancer. When this happens, cancer cells continue growing uncontrollably, avoid natural cell death, and become resistant to hormone therapy.

Capivast 200 mg blocks abnormal AKT activity, interrupting the signaling responsible for uncontrolled tumor growth. This targeted action may reduce cancer progression while restoring sensitivity to endocrine treatment.

How Does Capivast 200 mg Work?

The active ingredient in Capivast 200 mg, Capivasertib, selectively inhibits the AKT protein, one of the primary drivers of tumor development in cancers with PI3K/AKT pathway activation.

Many breast cancers develop mutations that continuously activate this pathway. These abnormal signals allow malignant cells to:

• Multiply rapidly
• Resist programmed cell death (apoptosis)
• Spread to surrounding tissues
• Develop resistance to endocrine therapy

By blocking AKT signaling, Capivast 200 mg helps:

• Slow cancer cell growth
• Reduce tumor cell survival
• Improve the effectiveness of hormone therapy
• Delay disease progression
• Help overcome endocrine resistance
• Suppress abnormal cellular signaling

Because Capivast 200 mg specifically targets molecular abnormalities within cancer cells, it differs significantly from traditional chemotherapy, which affects both healthy and cancerous rapidly dividing cells.

Medical Uses of Capivast 200 mg

Treatment of HR-Positive, HER2-Negative Advanced Breast Cancer

The primary indication for Capivast 200 mg is the treatment of adults with hormone receptor-positive (HR-positive), HER2-negative locally advanced or metastatic breast cancer whose disease has progressed following previous endocrine therapy.

Patients whose tumors have specific genetic alterations often derive the greatest clinical benefit from treatment.

Combination Therapy with Fulvestrant

One of the most common treatment strategies involves using Capivast 200 mg together with Fulvestrant.

Fulvestrant works by blocking and degrading estrogen receptors on breast cancer cells, while Capivasertib inhibits the AKT pathway responsible for treatment resistance.

Together, these medicines provide a dual mechanism that may:

• Enhance endocrine therapy response
• Delay cancer progression
• Improve progression-free survival
• Reduce resistance to previous hormonal treatment

Precision Medicine for Genetic Mutations

Capivast 200 mg is especially beneficial for patients whose tumors contain alterations in the following genes:

• PIK3CA mutation
• AKT1 mutation
• PTEN alteration

These mutations activate the PI3K/AKT pathway, allowing tumors to grow despite previous endocrine therapy.

Targeting these molecular abnormalities enables Capivast 200 mg to deliver more personalized cancer treatment.

Benefits of Capivast 200 mg

Patients receiving Capivast 200 mg may experience several important therapeutic benefits.

Precision Targeted Therapy

Rather than attacking all rapidly dividing cells, Capivast 200 mg selectively blocks abnormal cancer signaling pathways, helping preserve many healthy tissues.

Helps Overcome Hormone Therapy Resistance

Many advanced breast cancers eventually stop responding to endocrine therapy. Capivasertib may restore treatment sensitivity by blocking AKT-mediated resistance mechanisms.

Oral Administration

Unlike intravenous chemotherapy, Capivast 200 mg is taken by mouth, allowing many patients to continue treatment from home without frequent infusion appointments.

Supports Longer Disease Control

Clinical studies have shown that combining Capivasertib with endocrine therapy may extend progression-free survival in eligible patients.

Personalized Cancer Treatment

Patients whose tumors carry PIK3CA, AKT1, or PTEN mutations may benefit from a more individualized treatment approach using Capivast 200 mg.

Non-Chemotherapy Option

Because it is a targeted therapy, Capivast 200 mg offers an alternative to conventional chemotherapy for appropriately selected patients.

Who May Benefit from Capivast 200 mg?

Your oncologist may recommend Capivast 200 mg if you:

• Have HR-positive, HER2-negative advanced breast cancer
• Have metastatic breast cancer
• Experienced disease progression after endocrine therapy
• Have tumors with PIK3CA, AKT1, or PTEN mutations
• Are eligible for combination treatment with Fulvestrant
• Require an oral targeted therapy instead of conventional chemotherapy

Capivast 200 mg Dosage and Administration

Capivast 200 mg should always be taken exactly as prescribed by your oncologist or healthcare provider. Do not change your dose, stop treatment, or restart the medicine without professional medical advice.

The recommended dosage depends on your medical condition, overall health, laboratory results, response to treatment, and whether you are taking other anticancer medicines such as Fulvestrant.

Recommended Dosing Schedule

Capivasertib is generally administered using an intermittent dosing schedule to help maximize treatment effectiveness while reducing the risk of adverse effects.

A typical treatment cycle includes:

• Take Capivast 200 mg twice daily
• Maintain approximately 12 hours between each dose
• Continue treatment for 4 consecutive days
• Follow with 3 days without medication
• Repeat this weekly schedule unless instructed otherwise by your healthcare provider

Always follow the treatment plan provided by your oncology specialist.

How to Take Capivast 200 mg

To achieve the best possible treatment results:

• Swallow the tablet whole with a full glass of water.
• Take it with or without food, as directed by your healthcare provider.
• Do not crush, chew, split, or break the tablet.
• Avoid taking damaged or broken tablets.
• Take each dose at approximately the same times every treatment day.
• Continue therapy until your doctor advises you to stop.

Maintaining a consistent dosing schedule helps ensure stable drug levels in your body.

Missed Dose Instructions

If you forget to take a dose of Capivast 200 mg:

• Take the missed dose only if instructed by your healthcare provider or according to your prescribing information.
• If it is close to your next scheduled dose, skip the missed dose.
• Never take two doses at the same time to make up for a missed dose.

If vomiting occurs after taking your medication:

• Do not take an additional replacement dose.
• Resume your normal dosing schedule with the next planned dose.

If you are unsure what to do, contact your oncology team for guidance.

Possible Side Effects of Capivast 200 mg

Like all cancer medicines, Capivast 200 mg may cause side effects. Not everyone experiences them, and many can be managed with appropriate medical care.

Common Side Effects

Patients may experience:

• Diarrhea
• Nausea
• Vomiting
• Fatigue
• Weakness
• Decreased appetite
• Mouth sores (stomatitis)
• Skin rash
• Dry skin
• Itching
• Elevated blood sugar (hyperglycemia)

Your healthcare provider may recommend supportive medications to help manage these symptoms during treatment.

Serious Side Effects

Seek immediate medical attention if you develop:

• Persistent or severe diarrhea
• Signs of dehydration
• Severe skin rash, blistering, or peeling
• High fever
• Difficulty breathing
• Severe allergic reactions
• Uncontrolled blood sugar levels
• Extreme weakness or dizziness

Prompt treatment can help prevent serious complications.

Benefits of Capivast 200 mg

When prescribed appropriately, Capivast 200 mg offers several important clinical advantages.

Precision Cancer Treatment

Targets the AKT signaling pathway involved in cancer growth while limiting unnecessary effects on healthy tissues.

Helps Delay Disease Progression

Clinical studies have demonstrated improved progression-free survival in eligible patients receiving Capivasertib with Fulvestrant.

Oral Medication

Convenient tablet formulation allows patients to receive treatment at home without intravenous chemotherapy infusions.

Supports Hormone Therapy

Capivast 200 mg enhances the effectiveness of endocrine therapy by reducing resistance mechanisms within cancer cells.

Personalized Medicine

Patients with PIK3CA, AKT1, or PTEN mutations may achieve greater clinical benefit through targeted treatment.

Warnings and Precautions

Before starting Capivast 200 mg, inform your healthcare provider about all medical conditions and medications.

Blood Sugar Monitoring

Capivasertib may increase blood glucose levels.

Patients with:

• Diabetes
• Prediabetes
• Metabolic syndrome

may require more frequent blood sugar monitoring throughout treatment.

Severe Diarrhea

Diarrhea is among the most frequently reported adverse reactions.

Patients should:

• Drink plenty of fluids.
• Monitor bowel movements.
• Contact their healthcare provider if diarrhea becomes severe or persistent.

Untreated diarrhea can result in dehydration and electrolyte imbalance.

Skin Reactions

Some patients may experience:

• Rash
• Redness
• Peeling skin
• Blistering

Report any significant skin changes promptly to your healthcare provider.

Pregnancy

Capivast 200 mg may cause harm to an unborn baby.

Women of childbearing potential should:

• Use effective contraception during treatment.
• Continue contraception for the period recommended by their healthcare provider after completing therapy.

Notify your doctor immediately if pregnancy occurs.

Breastfeeding

Breastfeeding is generally not recommended while receiving Capivast 200 mg because it is unknown whether Capivasertib passes into breast milk.

Liver and Kidney Function

Patients with liver or kidney impairment may require:

• Regular laboratory monitoring
• Dose adjustments
• Additional clinical assessment

Always attend scheduled follow-up appointments.

Drug Interactions

Capivast 200 mg may interact with several medications that affect the CYP3A enzyme system.

Always provide your healthcare provider with a complete list of:

• Prescription medicines
• Over-the-counter medications
• Vitamins
• Herbal supplements

before beginning treatment.

CYP3A Inhibitors

Strong CYP3A inhibitors may increase Capivasertib concentrations in the bloodstream, raising the risk of side effects.

Examples include:

• Certain antifungal medications
• Some antibiotics
• Several antiviral medicines

CYP3A Inducers

Strong CYP3A inducers may reduce the effectiveness of Capivast 200 mg.

Examples include:

• Rifampicin
• Certain anti-seizure medications
• St. John’s Wort
• Other enzyme-inducing herbal products

Avoid starting or stopping medications without consulting your oncology specialist.

Storage Instructions

Store Capivast 200 mg according to the manufacturer’s recommendations.

• Store below 25°C (77°F).
• Keep in the original packaging.
• Protect from excessive heat and moisture.
• Store away from direct sunlight.
• Keep out of the reach of children and pets.
• Do not use after the expiration date.

Dispose of unused medicine according to local pharmaceutical disposal guidelines.

Final Summary

Capivast 200 mg (Capivasertib) is an innovative targeted therapy developed for adults with HR-positive, HER2-negative advanced or metastatic breast cancer whose disease has progressed after endocrine therapy. By selectively inhibiting the AKT signaling pathway, it addresses one of the key mechanisms that drive tumor growth and treatment resistance.

When used in combination with Fulvestrant, Capivast 200 mg may improve progression-free survival, enhance the effectiveness of hormone therapy, and provide a personalized treatment option for patients with PIK3CA, AKT1, or PTEN genetic alterations.

Because this medicine can cause significant side effects and drug interactions, treatment should always be managed by an experienced oncology specialist. Regular monitoring, adherence to the prescribed dosing schedule, and open communication with your healthcare team are essential for achieving the safest and most effective outcomes.

Frequently Asked Questions (FAQs)

1.What is Capivast 200 mg used for?

Ans: Capivast 200 mg is a prescription medicine containing Capivasertib, an AKT inhibitor used with Fulvestrant to treat adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer whose disease has progressed after endocrine therapy. It is particularly beneficial for patients whose tumors have PIK3CA, AKT1, or PTEN genetic alterations.

2.How does Capivast 200 mg work?

Ans: Capivast 200 mg blocks the AKT protein, an important component of the PI3K/AKT signaling pathway. By inhibiting this pathway, the medicine slows cancer cell growth, reduces tumor survival, and may help overcome resistance to hormone therapy.

3.Can Capivast 200 mg be taken alone?

Ans: Capivast 200 mg is commonly prescribed in combination with Fulvestrant. Your oncologist will determine the most appropriate treatment plan based on your diagnosis, genetic testing results, and previous therapies.

4.What are the most common side effects of Capivast 200 mg?

Ans: Common side effects may include:

• Diarrhea
• Nausea
• Vomiting
• Fatigue
• Skin rash
• Mouth sores
• Elevated blood sugar levels
• Decreased appetite

Contact your healthcare provider if side effects become severe or persistent.

5.Is Capivast 200 mg chemotherapy?

Ans: No. Capivast 200 mg is not a traditional chemotherapy drug. It is a targeted therapy that selectively inhibits the AKT signaling pathway involved in cancer growth, allowing for a more personalized treatment approach.

Who should not take Capivast?

Capivast 200 mg may not be suitable for everyone. Inform your healthcare provider if you:

• Are pregnant or planning to become pregnant
• Are breastfeeding
• Have liver or kidney disease
• Have uncontrolled diabetes
• Are taking medications that strongly affect the CYP3A enzyme system

Your doctor will determine whether this medicine is appropriate for your condition.

Why Choose Capivast 200 mg?

Patients and healthcare professionals increasingly recognize Capivast as an important targeted therapy option because it offers:

• Advanced precision-targeted treatment
• Oral tablet for convenient at-home administration
• Proven AKT pathway inhibition
• Enhanced effectiveness when combined with Fulvestrant
• Potential to overcome endocrine therapy resistance
• Personalized treatment for tumors with specific genetic mutations

Its targeted mechanism helps address the underlying molecular drivers of certain breast cancers while supporting improved clinical outcomes in eligible patients.

Why Buy Capivast Online?

Purchasing Capivast 200 mg from a trusted international online pharmacy can provide several advantages, including:

• Competitive pricing
• Access to high-quality oncology medicines
• Secure worldwide shipping
• Reliable customer support
• Convenient online ordering
• Authentic pharmaceutical products from reputable manufacturers

Always ensure you purchase prescription medicines from a licensed and reputable supplier and use them only under the supervision of a qualified oncology specialist.